FDA authorizes new monoclonal antibody treatment to fight omicron
(WASHINGTON) -- The Food and Drug Administration has authorized a new monoclonal antibody treatment for COVID-19, shown to hold up against the omicron variant and BA.2 subvariant.The drug, called bebtelovimab from Eli Lilly, is a monoclonal therapy meant for COVID-19 patients as young as...